Is Upadacitinib available in China?

The original drug Upadacitinib (Upadacitinib) has been approved by the State Food and Drug Administration for marketing in China. Upadacitinib has subsequently been included in China's national reimbursement drug list. It has been approved for the treatment of several indications, including atopic dermatitis, active psoriatic arthritis, as well as moderate to severe rheumatoid arthritis, active ulcerative colitis and active Crohn's disease. Upadatinib has also entered the scope of Class B medical insurance, and is only reimbursed for eligible patients. It is sold under the trade name Ruifu/RINVOQ, and the price of each box of 15mg*28 tablets may be around 3,000 yuan.